[1]万璐,吴小军.铜绿假单胞菌Ⅲ型分泌系统效应蛋白的作用及机制研究进展[J].新乡医学院学报,2022,39(11):1092-1095.[doi:10.7683/xxyxyxb.2022.11.019]
　WAN Lu,WU Xiaojun.Research progress on effect of the effector protein of type Ⅲ secretion system of Pseudomonas aeruginosa and its mechanism[J].Journal of Xinxiang Medical University,2022,39(11):1092-1095.[doi:10.7683/xxyxyxb.2022.11.019]
点击复制

铜绿假单胞菌Ⅲ型分泌系统效应蛋白的作用及机制研究进展
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
39
期数:
2022年11
页码:
1092-1095
栏目:
综述
出版日期:
2022-11-05

文章信息/Info

Title:
Research progress on effect of the effector protein of type Ⅲ secretion system of Pseudomonas aeruginosa and its mechanism
作者:
万璐; 吴小军
(武汉大学人民医院呼吸和危重症科，湖北　武汉　430060）
Author(s):
WAN Lu; WU Xiaojun
(Department of Respiratory and Critical Medicine，Renmin Hospital of Wuhan University，Wuhan 430060，Hubei Province,China)
关键词:
铜绿假单胞菌; Ⅲ型分泌系统; 效应蛋白; 抑制剂
Keywords:
Pseudomonas aeruginosa; type Ⅲ secretion system; effector proteins; inhibitor
分类号:
R446.5
DOI:
10.7683/xxyxyxb.2022.11.019
文献标志码:
A
摘要:
铜绿假单胞菌（PA）是一种引起院内感染的革兰阴性病原菌，PA可通过Ⅲ型分泌系统（T3SS）将效应蛋白转入宿主细胞内而引起急性感染，并在效应蛋白的作用下逃避吞噬细胞的吞噬作用。因此，明确T3SS及其效应蛋白的激活、调控机制有助于为PA的治疗提供新的思路。本文对T3SS的组成和功能、效应蛋白的分泌方式及作用机制进行综述，旨在为新型抗菌药物的研发提供理论基础。
Abstract:
Pseudomonas aeruginosa (PA) is a gram-negative pathogenic bacterium that causes nosocomial infection,PA can transfer the effector proteins into host cells through the type Ⅲ secretion system (T3SS) to cause acute infection,and it can evade the phagocytosis of phagocytes under the action of effector proteins.Therefore,clarifying the mechanism of activation and regulatory of T3SS and its effector proteins will help to provide new ideas for the treatment of PA.This article reviews the composition and function of T3SS,the secretion mode and mechanism of effector proteins,in order to provide a theoretical basis for the development of new antibacterial drugs.

参考文献/References:

［1］　THI M T T，WIBOWO D，REHM B H A.Pseudomonas aeruginosa biofilms［J］.Int J Mol Sci，2020，21(22):8671.
［2］　ZILBERBERG M D，NATHANSON B H，SULHAM K，et al.A novel algorithm to analyze epidemiology and outcomes of carbapenem resistance among patients with hospital-acquired and ventilator-associated pneumonia:a retrospective cohort study［J］.Chest，2019，155(6):1119-1130.
［3］　KOCSIS B，GULYS D，SZAB D.Diversity and distribution of resistance markers in Pseudomonas aeruginosa international high-risk clones［J］.Microorganisms，2021，9(2):359.
［4］　JURADO-MARTN I，SAINZ-MEJAS M，MCCLEAN S.Pseudomonas aeruginosa:an audacious pathogen with an adaptable arsenal of virulence factors［J］.Int J Mol Sci，2021，22(6):3128.
［5］　YAHR T L,BARBIERI J T,FRANK D W.Genetic relationship between the 53- and 49-kilodalton forms of exoenzyme S from Pseudomonas aeruginosa［J］.J Bacteriol,1996,178(5):1412-1419.
［6］　HORNA G，RUIZ J.Type 3 secretion system of Pseudomonas aeruginosa［J］.Microbiol Res，2021，246:126719.
［7］　张鸿，陈炜.铜绿假单胞菌Ⅲ型分泌系统结构及调控机制的研究进展［J］.中国感染与化疗杂志，2020，20(3):335-339.
ZHANG H，CHEN W.Research updates on the structure and regulatory mechanism of type Ⅲ secretion system in Pseudomonas aeruginosa［J］.Chin J Infect Chemother，2020，20(3):335-339.
［8］　HARDY K S，TUCKEY A N，RENEMA P，et al.ExoU induces lung endothelial cell damage and activates pro-inflammatory caspase-1 during Pseudomonas aeruginosa infection［J］.Toxins (Basel)，2022，14(2):152.
［9］　HARDY K S，TESSMER M H，FRANK D W，et al.Perspectives on the Pseudomonas aeruginosa type Ⅲ secretion system effector ExoU and its subversion of the host innate immune response to infection［J］.Toxins (Basel)，2021，13(12):880.
［10］　FOULKES D M，MCLEAN K，ZHENG Y，et al.A pipeline to evaluate inhibitors of the Pseudomonas aeruginosa exotoxin U［J］.Biochem J，2021，478(3):647-668.
［11］　TESSMER M H，DECERO S A，DEL ALAMO D，et al.Charac-terization of the ExoU activation mechanism using EPR and integrative modeling［J］.Sci Rep，2020，10(1):19700.
［12］　RAO L，DE LA ROSA I，XU Y，et al.Pseudomonas aeruginosa survives in epithelia by ExoS-mediated inhibition of autophagy and mTOR［J］.EMBO Rep，2021，22(2):e50613.
［13］　VOTH S，GWIN M，FRANCIS C M，et al.Virulent Pseudomonas aeruginosa infection converts antimicrobial amyloids into cytotoxic prions［J］.FASEB J，2020，34(7):9156-9179.
［14］　KHODAYARY R，NIKOKAR I，MOBAYEN M R，et al.High incidence of type Ⅲ secretion system associated virulence factors (exoenzymes) in Pseudomonas aeruginosa isolated from Iranian burn patients［J］.BMC Res Notes，2019，12(1):28.
［15］　KROKEN A R，GAJENTHRA KUMAR N，YAHR T L，et al.Exotoxin S secreted by internalized Pseudomonas aeruginosa delays lytic host cell death［J］.PLoS Pathog，2022，18(2):e1010306.
［16］　ARMENTROUT E I,KUNDRACIK E C,RIETSCH A.Cell-type-specific hypertranslocation of effectors by the Pseudomonas aeruginosa type Ⅲ secretion system［J］.Mol Microbiol,2021,115(2):305-319.
［17］　GARAI P，BERRY L，MOUSSOUNI M，et al.Killing from the inside:intracellular role of T3SS in the fate of Pseudomonas aeruginosa within macrophages revealed by mgtC and oprF mutants［J］.PLoS Pathog，2019，15(6):e1007812.
［18］　PARK T.Crk and CrkL as therapeutic targets for cancer treatment［J］.Cells，2021，10(4):739.
［19］　FU Q，YU Z.Phosphoglycerate kinase 1 (PGK1) in cancer:a promising target for diagnosis and therapy［J］.Life Sci，2020，256:117863.
［20］　MOHAMED M F，GUPTA K，GOLDUFSKY J W，et al.CrkII/Abl phosphorylation cascade is critical for NLRC4 inflammasome activity and is blocked by Pseudomonas aeruginosa ExoT［J］.Nat Commun，2022，13(1):1295.
［21］　MOHAMED M F，WOOD S J，ROY R，et al.Pseudomonas aeruginosa ExoT induces G1 cell cycle arrest in melanoma cells［J］.Cell Microbiol，2021，23(8):e13339.
［22］　MANCL J M，SUAREZ C，LIANG W G，et al.Pseudomonas aeruginosa exoenzyme Y directly bundles actin filaments［J］.J Biol Chem，2020，295(11):3506-3517.
［23］　BELYY A，MERINO F，MECHOLD U，et al.Mechanism of actin-dependent activation of nucleotidyl cyclase toxins from bacterial human pathogens［J］.Nat Commun，2021，12(1):6628.
［24］　WAGENER B M，ANJUM N，CHRISTIAANS S C，et al.Exoenzyme Y contributes to end-organ dysfunction caused by Pseudomonas aeruginosa pneumonia in critically ill patients:an exploratory study［J］.Toxins (Basel)，2020，12(6):369.
［25］　SILISTRE H，RAOUX-BARBOT D，MANCINELLI F，et al.Prevalence of ExoY activity in Pseudomonas aeruginosa reference panel strains and impact on cytotoxicity in epithelial cells［J］.Front Microbiol，2021，12:666097.
［26］　赵轩,江晓烽,秦江雷,等.载铜绿假单胞菌OprF和PcrV基因联合DNA疫苗的水凝胶缓释系统的构建及免疫效力评价［J］.解放军医学杂志,2022,47(9):871-878.
ZHAO X,JIANG X F,QIN J L，et al.Construction and immune efficacy evaluation of a hydrogel sustained-release system containing a combined DNA vaccine of Pseudomonas aeruginosa OprF and PcrV genes［J］.Med J Chin PLA,2022,47(9):871-878.
［27］　TRIGGS C T，TANSKI J M.Crystallographic and spectroscopic characterization of 3-chloro-5-fluoro-salicyl-aldehyde［J］.Acta Crystallogr E Crystallogr Commun，2020，76(Pt 12):1810-1812.
［28］　SHARMA P，ELOFSSON M，ROY S.Attenuation of Pseudomonas aeruginosa infection by INP0341，a salicylidene acylhydrazide，in a murine model of keratitis［J］.Virulence，2020，11(1):795-804.
［29］　MOIR D T，BOWLIN N O，BERUBE B J，et al.A structure-function-inhibition analysis of the Pseudomonas aeruginosa type Ⅲ secretion needle protein PscF［J］.J Bacteriol，2020，202(18):e00055-e00074.
［30］　ZHAO X,YU Z,DING T.Quorum-sensing regulation of antimicrobial resistance in bacteria［J］.Microorganisms，2020，8(3):425.
［31］　GARCA-REYES S,SOBERN-CHVEZ G,COCOTL-YANEZ M.The third quorum-sensing system of Pseudomonas aeruginosa:pseudomonas quinolone signal and the enigmatic PqsE protein［J］.J Med Microbiol,2020,69(1):25-34.
［32］　PENA R T，BLASCO L，AMBROA A，et al.Relationship between quorum sensing and secretion systems［J］.Front Microbiol，2019，10:1100.
［33］　SCHTZ C,HO D K,HAMED M M,et al.A new PqsR inverse agonist potentiates tobramycin efficacy to eradicate Pseudomonas aeruginosa biofilms［J］.Adv Sci (Weinh)，2021,8(12):e2004369.
［34］　WARRIER A,SATYAMOORTHY K,MURALI T S.Quorum-sensing regulation of virulence factors in bacterial biofilm［J］.Future Microbiol,2021,16:1003-1021.
［35］　ZHANG P,GUO Q,WEI Z,et al.Baicalin represses type three secretion system of Pseudomonas aeruginosa through PQS system［J］.Molecules,2021,26(6):1497.
［36］　WEI Q,BHASME P,WANG Z,et al.Chinese medicinal herb extract inhibits PQS-mediated quorum sensing system in Pseudomonas aeruginosa［J］.J Ethnopharmacol,2020,248:112272.
［37］　LEE V T，PUKATZKI S，SATO H，et al.Pseudolipasin A is a specific inhibitor for phospholipase A2 activity of Pseudomonas aeruginosa cytotoxin ExoU［J］.Infect Immun，2007，75(3):1089-1098.
［38］　KIM D，BAEK J，SONG J，et al.Identification of arylsulfonamides as ExoU inhibitors［J］.Bioorg Med Chem Lett，2014，24(16):3823-3825.
［39］　MOIR D T,OPPERMAN T J,ARON Z D,et al.Adjunctive therapy for multidrug-resistant bacterial infections:type Ⅲ secretion system and efflux inhibitors［J］.Drug Discov Today,2021,26(9):2173-2181.

相似文献/References:

[1]屈艳,张崇,张春晓.铜绿假单胞菌耐氨基糖苷类相关耐药基因的检测[J].新乡医学院学报,2012,29(07):502.
[2]陈松建,王书伟,张　改,等.铜绿假单胞菌临床感染特征及其产超广谱β-内酰胺酶危险因素分析[J].新乡医学院学报,2019,36(8):755.[doi:10.7683/xxyxyxb.2019.08.013]
　CHEN Song-jian,WANG Shu-wei,ZHANG Gai,et al.Clinical infections characteristic of Pseudomonas aeruginosa and it′s risk factors for producing extended-spectrum β-lactamase[J].Journal of Xinxiang Medical University,2019,36(11):755.[doi:10.7683/xxyxyxb.2019.08.013]
[3]陆建福,王　伟,李华信,等.2012～2015年河南省4所医院铜绿假单胞菌分布及耐药性分析[J].新乡医学院学报,2017,34(11):994.[doi:10.7683/xxyxyxb.2017.11.010]
　LU Jian-fu,WANG Wei,LI Hua-xin,et al.Clinical distribution and resistance analysis of pseudomonas aeruginosa in the four hospitals of Henan province during 2012-2015[J].Journal of Xinxiang Medical University,2017,34(11):994.[doi:10.7683/xxyxyxb.2017.11.010]

更新日期/Last Update: 2022-11-05